HSP90AB1 and neoplasm: By simultaneously inhibiting ER and Hsp90, a multitarget drug can not only tackle the primary tumor growth mechanism mediated by ER but also interfere with cellular stress mechanisms and the stabilization of oncoproteins mediated by Hsp90.